Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Teva Mulling Bid for Mylan But Dismisses Rumors and Remains Committed to Perrigo Company

Written by: | support@biospace.com | Dated: Monday, April 20th, 2015

Rumors that Teva Pharmaceutical Industries Ltd. (TEVA) and Mylan Inc. (MYL) are finally ready to merge have once again been roiling the market, after people familiar with the matter told Bloomberg News they expect a formal bid from Teva for Mylan soon, in a move that will make one of the world’s largest global generic-drug companies.

“Teva hasn’t made a formal approach yet, the people said, though Mylan is aware of the Israeli company’s interest,” said Bloomberg Monday. “Teva is evaluating the purchase internally and has also approached advisers about the potential bid and financing, the people said, asking not to be identified discussing private information.”

Earlier this month Mylan made an unsolicited $28.9 billion bid for Perrigo Co., a move which Wall Street has taken as a catalyst for Teva to pounce before Mylan becomes a larger, and much more expensive, target. Mylan has said, however, that it remains committed to its deal with Perrigo, refuting a Teva deal soundly in a statement on Friday.

“We have studied the potential combination of Mylan and Teva for some time and we believe it is clear that such a combination is without sound industrial logic or cultural fit,” Robert J. Coury, Mylan’s executive chairman, said.

Mylan does have a host of attractive assets that have been tempting to larger drugmaker, including recent clues from the U.S. Food and Drug Administration that Mylan’s generic ANDA, which is a stand-in for Natco’s multiple sclerosis drug Copaxone. Umer Raffat, a biotech analyst at ISI Evercore, said Monday that Mylan is poised to receive approval for that drug, which would quickly be rushed to market. Teva lost patent protection for Copaxone last July after a U.S. Federal Appeals Court found the patent protecting the drug would expire in May 2014, not September 2015.

“My base case continues to be that Mylan will get its Copaxone approved,” said Raffat, “and it intends to commercialize it at the time of market formation.”

Mylan (MYL) is one of the largest generics and specialty pharmaceutical companies in the world, with about 1,400 different products it markets. Teva also focuses on generics, as well as specialty drugs and active pharmaceutical ingredients. It has a portfolio of more than 1,000 molecules, employs more than 45,000 people worldwide and sells in 60 countries.

Analysts have continued to dismiss the possible marriage, saying rumors the two might be merging aren’t credible and would do very little to solve Teva’s current growth problems even if the companies did blend, said Wells Fargo analyst Michael Faerm.

Calling it strategically unlikely, Faerm said continued buzz about a possible deal between the Israeli drugmaker and Mylan was overblown.

Faerm said acquiring a generic drugs company is probably not a top priority for Teva, while Mylan has not indicated it would even be a willing seller, even if it currently in the process of designing a generic for Copaxone.

Teva reported earlier this year that each month of delay in generic competition for Copaxone adds about $78 million to the company’s net revenue and $0.08 to its share price.

David Maris, analyst with BMO, said in a note in March that most of the rumors so far about the deal have been baseless and are likely from sources “just putting out fluff.”

Maris’s skepticism is related to Mylan recently acquiring some of Abbott Laboratories (ABT)’s sagging European generics as part of a tax inversion deal, pointing out that if Teva bought Mylan, the Israeli company would have two choices: Mylan to Israel, which has major tax disadvantages, or compete an inversion and change its domicile to the Netherlands, which would violate Teva’s bylaws.

Maris also believes the acquisition wouldn’t be very good strategically. “Mylan bought the Abbott products to focus in on Europe—particularly France—and that’s not an area Teva is interested in,” he wrote.

In addition, Maris thinks that Teva’s debt capacity is too small to pull off a Mylan deal. Mylan has a $22 billion-plus market cap, and with a premium and the company’s debt, the deal would be at about $30 billion. “They’re not going to go to junk status,” Maris said in a note, “just to finance this deal.”

Source: BioSpace

 

April 20, 2015
By Riley McDermid, BioSpace.com Breaking News Sr. Editor

Leave a Reply

Be the First to Comment!


 

Ad Right Top

MedAdNews

FebcoverjpegthumbExtensive pharmaceutical business and marketing intelligence. If you would like to purchase a back issue, please contact our customer service department at MDAD@kmpsgroup.com, or call 800-869-6882.

February 2015 Focus: Agenda 2015, Top 10 Pipelines, SFE

Subscribe

Ad Right Bottom

Marketing Communications Directory

Marketing Communications Directory

Healthcare Communications Agencies & Marketing Services Directory

Contract Research Directory

Contract Research Directory

Qualified Clinical Research Organizations Directory

Main Navigation
Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.